PBLSParabilis Medicines, Inc.vs its industry peers
A metric-by-metric comparison of Parabilis Medicines, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PBLSThis | $4.9B#2 | — | 4.7x#6 | — | — | — | — | 0.0%#3 | — | — | — | — |
| EWTX | $5.0B#1 | — | 11.1x#8 | — | — | -25.4%#6 | — | -0.0%#4 | -50.9%#3 | — | 228.7%#1 | — |
| ACAD | $4.7B#3 | 12.3x#1 | 3.6x#3 | 4.4x#2 | 11.9%#3 | 73.0%#1 | 9.8%#2 | 29.9%#1 | 11.4%#1 | — | 13.1%#7 | — |
| MANE | $4.5B#4 | — | 5.5x#7 | — | — | -164.3%#8 | — | -8.6%#5 | — | — | — | — |
| TNGX | $4.0B#5 | — | 3.9x#4 | 64.6x#4 | 48.3%#2 | 22.0%#4 | -178.4%#4 | -9.9%#7 | — | — | 213.5%#2 | — |
| AMLX | $3.7B#7 | — | 15.5x#9 | — | -100.0%#5 | 52.0%#3 | — | -60.5%#9 | — | — | 161.0%#4 | — |
| IDYA | $3.7B#6 | — | 3.1x#1 | 17.1x#3 | 3024.4%#1 | 58.6%#2 | -72.8%#3 | -9.5%#6 | — | — | 58.6%#5 | — |
| ELVN | $3.7B#8 | — | 4.1x#5 | — | — | -16.5%#5 | — | -11.6%#8 | — | — | 163.0%#3 | — |
| OGN | $3.6B#9 | 17.5x#2 | 3.6x#2 | 0.6x#1 | -2.9%#4 | -78.4%#7 | 14.9%#1 | 18.6%#2 | 4.9%#2 | 5#1 | 34.2%#6 | 2.4%#1 |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice